转移性食管胃癌姑息性全身治疗的医院年诊疗量与生存结局的关系
该研究基于荷兰癌症登记库2005至2013年诊断的转移性食管癌4078例和胃癌5425例,按三种高危量定义分析医院年诊疗量与生存的关系。食管癌在高手术量中心和高治疗量中心治疗者死亡风险降低,胃癌仅在高手术量中心治疗者结局更优。
要点
- 转移性食管癌中位总生存20周(95%CI 19-21周),胃癌16周(95%CI 15-17周)。
- 食管癌高手术量中心调整HR 0.80(95%CI 0.70-0.91),高治疗量中心调整HR 0.88(95%CI 0.78-0.99)。
- 胃癌高手术量中心调整HR 0.83(95%CI 0.74-0.92),结局更优。
核心结论
- 接受姑息性全身治疗的食管胃癌患者生存改善与在高治疗量中心和高手术量中心治疗相关。
研究设计与样本
- 基于荷兰癌症登记库,纳入2005至2013年诊断的转移性食管癌4078例和转移性胃癌5425例。
- 按三种高危量定义分析:高发病率中心、高治疗量中心和高手术量中心。
- 采用多变量logistic回归分析姑息性化疗实施的独立预测因素,多变量Cox比例风险回归分析高容量中心对生存的影响。
主要发现
- 转移性食管癌中位总生存20周(95%CI 19-21周),转移性胃癌中位总生存16周(95%CI 15-17周)。
- 食管癌患者在高手术量中心治疗调整HR 0.80(95%CI 0.70-0.91),在高治疗量中心治疗调整HR 0.88(95%CI 0.78-0.99),死亡风险降低。
- 胃癌患者在高手术量中心治疗调整HR 0.83(95%CI 0.74-0.92),结局更优。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Palliative systemic therapy has been shown to improve survival in metastatic oesophagogastric cancer. Administration of palliative systemic therapy in metastatic oesophagogastric cancer varies between hospitals. We aimed to explore the association between the annual hospital volume of oesophagogastric cancer patients and survival. METHODS: Patients diagnosed in the Netherlands between 2005 and 2013 with metastatic oesophagogastric cancer were identified in the Netherlands Cancer Registry. Patients were attributed according to three definitions of high volume: (1) high-volume incidence centre, (2) high-volume treatment centre and (3) high-volume surgical centre. Independent predictors for administration of palliative chemotherapy were evaluated by means of multivariable logistic regression analysis, and multivariable Cox proportional hazard regression analysis was performed to assess the impact of high-volume centres on survival. RESULTS: Our data set comprised 4078 patients with metastatic oesophageal cancer, and 5425 patients with metastatic gastric cancer, with a median overall survival of 20 weeks (95% confidence interval [CI] 19-21 weeks) and 16 weeks (95% CI 15-17 weeks), respectively. Patients with oesophageal cancer treated in a high-volume surgical centre (adjusted hazard ratio [HR] 0.80, 95% CI 0.70-0.91) and a high-volume treatment centre (adjusted HR 0.88, 95% CI 0.78-0.99) exhibited a decreased risk of death. For gastric cancer, patients treated in a high-volume surgical centre (adjusted HR 0.83, 95% CI 0.74-0.92) had a superior outcome. CONCLUSION: Improved survival in patients undergoing palliative systemic therapy for oesophagogastric cancer was associated with treatment in high-volume treatment and surgical centres. Further research should be implemented to explore which specific factors of high-volume centres are associated with improved outcomes.
引用
- Haj Mohammad N, Bernards N, van Putten M, et al. Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer. Eur J Cancer. 2017. PMID: 28412586. doi:10.1016/j.ejca.2017.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。